Amgen finalises investment as Chinese biopharmaceuticals seem a strong prospect in 2020

Richard Tadd Industry News

The California-based multinational giant Amgen recently finalised an investment of $2.8 billion in Chinese pharmaceuticals, and it seems that the trends of the 2010s will continue as China continues to assert itself as a major player in the global biotechnology and pharmaceutical trades. Amgen itself has aggressively expanded its global influence since 2011, doubling its geographic presence from around 50 …